相关实验视频
Updated: Jul 6, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
根据T1D儿童的时间和静态信息预测血糖
Alexander Marx1, Francesco Di Stefano1, Heike Leutheuser1
1Department of Computer Science, ETH Zurich, Zurich, Switzerland.
Frontiers in pediatrics
|December 29, 2023
概括
深度学习模型在结合静态患者数据时,可以改善1型糖尿病 (T1D) 儿童的血糖预测. 这些进展表明短期预测有前途,尽管长期预测仍然具有挑战性.
科学领域:
- 生物医学工程 生物医学工程
- 在医疗保健中的数据科学.
- 儿科内分泌学 儿科内分泌学
背景情况:
- 1型糖尿病 (T1D) 的管理需要准确的血糖预测,以防止危险的葡萄糖波动.
- 深度学习模型已经在成人T1D葡萄糖预测方面取得了成功,但它们在儿童中的有效性不太清楚.
- 儿童独特的生理学,包括身体活动和发育阶段,使得葡萄糖水平的预测变得复杂.
研究的目的:
- 评估最先进的深度学习方法对T1D儿童的短期和长期血糖预测的性能.
- 研究整合静态患者特征 (年龄,性别,BMI,基底胰岛素百分比) 对预测准确性的影响.
- 为了比较儿童和先前研究的成年人群之间的预测性能.
主要方法:
- 一项前性观察性研究,从患有T1D的儿童中收集一周的时间序列数据 (葡萄糖,碳水化合物,胰岛素,身体活动).
- 应用深度学习模型,包括扩展循环神经网络 (RNN) 和变压器,用于收集的数据集.
- 将静态患者特征集成到深度学习架构中,以增强预测能力.
主要成果:
- 整合静态患者特征显著改善了短期血糖预测的准确性 (例如,RMSE的X mmol/l为1分钟).
- 具有静态数据集成的循环神经网络变体 (LSTM,GRU) 在短期预测中表现最好.
- 预测性能在较长的预测时间段下降,总的来说,活跃儿童的葡萄糖预测比成年人更具挑战性.
结论:
- 静态患者数据集成增强了儿童T1D血糖预测的深度学习模型性能,特别是短期预测.
- 目前的模型显示,对T1D儿童的短期预测有希望的结果.
- 需要进行进一步的临床研究,以提高该人群中长期血糖预测的准确性和可靠性.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Diabetes: Symptoms, Diagnosis, and Complications
549
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
549
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Hypoglycemia and Glucagon
264
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
264
Insulin: Dosing Regimen and Adverse Effects
176
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
176
Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285

